Equities Analysts Set Expectations for COGT FY2025 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Investment analysts at Wedbush boosted their FY2025 earnings estimates for Cogent Biosciences in a research note issued on Monday, November 3rd. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earnings per share of ($1.99) for the year, up from their prior estimate of ($2.21). The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences’ Q4 2025 earnings at ($0.44) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.72) EPS.

Several other research firms also recently commented on COGT. Weiss Ratings reissued a “sell (e+)” rating on shares of Cogent Biosciences in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of Cogent Biosciences in a research note on Tuesday. JPMorgan Chase & Co. boosted their price objective on shares of Cogent Biosciences from $30.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 21st. Raymond James Financial initiated coverage on shares of Cogent Biosciences in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $30.00 target price for the company. Finally, Citigroup boosted their price target on Cogent Biosciences from $15.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cogent Biosciences has an average rating of “Moderate Buy” and a consensus price target of $20.83.

Cogent Biosciences Stock Performance

COGT opened at $14.13 on Wednesday. The business’s 50-day simple moving average is $14.25 and its 200 day simple moving average is $10.32. The firm has a market capitalization of $1.61 billion, a PE ratio of -7.94 and a beta of 0.41. Cogent Biosciences has a 52-week low of $3.72 and a 52-week high of $17.15.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings data on Tuesday, August 5th. The technology company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.02.

Institutional Trading of Cogent Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. grew its position in shares of Cogent Biosciences by 41.4% during the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after purchasing an additional 1,333 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Cogent Biosciences by 22.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,401 shares of the technology company’s stock worth $78,000 after acquiring an additional 1,003 shares during the period. CWM LLC raised its holdings in Cogent Biosciences by 25.3% in the 3rd quarter. CWM LLC now owns 5,582 shares of the technology company’s stock valued at $80,000 after acquiring an additional 1,126 shares in the last quarter. Strs Ohio bought a new stake in shares of Cogent Biosciences during the 1st quarter valued at $36,000. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Cogent Biosciences by 16.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 10,839 shares of the technology company’s stock worth $78,000 after purchasing an additional 1,543 shares in the last quarter.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.